Source:
University of Sheffield
Summary:
Researchers have found
vital new evidence on how to target and reverse the effects caused by
one of the most common genetic causes of Parkinson’s.
A microscope image of a cultured cell.
Researchers from the University of Sheffield have found vital new
evidence on how to target and reverse the effects caused by one of the
most common genetic causes of Parkinson's.
Mutations in a gene called LRRK2 carry a well-established risk for
Parkinson's disease, however the basis for this link is unclear.
The team, led by Parkinson's UK funded researchers Dr Kurt De Vos
from the Department of Neuroscience and Dr Alex Whitworth from the
Department of Biomedical Sciences, found that certain drugs could fully
restore movement problems observed in fruit flies carrying the LRRK2
Roc-COR Parkinson's mutation.
These drugs, deacetylase inhibitors, target the transport system and
reverse the defects caused by the faulty LRRK2 within nerve cells. The
study is published today (15 October 2014) month in Nature Communications.
Dr De Vos, a Lecturer in Translational Neuroscience at the
world-leading Sheffield Institute for Translational Neuroscience
(SITraN), said: "Our study provides compelling evidence that there is a
direct link between defective transport within nerve cells and movement
problems caused by the LRRK2 Parkinson's mutation in flies."
Co-investigator Dr Alex Whitworth explained: "We could also show that
these neuronal transport defects caused by the LRRK2 mutation are
reversible.
"By targeting the transport system with drugs, we could not only
prevent movement problems, but also fully restore movement abilities in
fruit flies who already showed impaired movement marked by a significant
decrease in both climbing and flight ability."
The LRRK2 gene produces a protein that affects many processes in the
cell. It is known to bind to the microtubules, the cells' transport
tracks. A defect in this transport system has been suggested to
contribute to Parkinson's disease. The researchers have investigated
this link and have now found the evidence that certain LRRK2 mutations
affect transport in nerve cells which leads to movement problems
observed in the fruit fly (Drosophila).
The team then used several approaches to show that preventing the
association of the mutant LRRK2 protein with the microtubule transport
system rescues the transport defects in nerve cells, as well as the
movement deficits in fruit flies.
Dr De Vos added: "We successfully used drugs called deacetylase
inhibitors to increase the acetylated form of α-tubulin within
microtubules which does not associate with the mutant LRRK2 protein. We
found that increasing microtubule acetylation had a direct impact on
cellular axonal transport.
"These are very promising results which point to a potential
Parkinson's therapy. However, further studies are needed to confirm that
this rescue effect also applies in humans."
Dr Beckie Port, Research Communications Officer at Parkinson's UK,
which helped to fund the study, said: "This research gives hope that,
for people with a particular mutation in their genes, it may one day be
possible to intervene and stop the progression of Parkinson's.
"The study has only been carried out in fruit flies, so much more
research is needed before we know if these findings could lead to new
treatment approaches for people with Parkinson's.
Parkinson's is a degenerative neurological condition, for which there
currently is no cure. The main symptoms of the condition are tremor,
slowness of movement and rigidity.
No comments